Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • Marek Lommatzsch - , University of Rostock (Author)
  • Klaus F Rabe - , LungenClinic Großhansdorf (Author)
  • Christian Taube - , University of Duisburg-Essen (Author)
  • Marcus Joest - , MVZ Lung and Allergy Center Bonn (Author)
  • Michael Kreuter - , University Hospital Heidelberg (Author)
  • Hubert Wirtz - , University Hospital Leipzig (Author)
  • Torsten Gerriet Blum - , Helios Hospital Group (Author)
  • Martin Kolditz - , Department of Internal Medicine I, Leibniz University Hannover (LUH) (Author)
  • Hilte Geerdes-Fenge - , University of Rostock (Author)
  • Ralf Otto-Knapp - , German Central Committee against Tuberculosis (Author)
  • Brit Häcker - , German Central Committee against Tuberculosis (Author)
  • Tom Schaberg - , Rothenburg (Author)
  • Felix C Ringshausen - , Leibniz University Hannover (LUH) (Author)
  • Claus F Vogelmeier - , University of Marburg (Author)
  • Niels Reinmuth - , Asklepios Clincs München-Gauting (Author)
  • Martin Reck - , LungenClinic Großhansdorf (Author)
  • Jens Gottlieb - , Leibniz University Hannover (LUH) (Author)
  • Stavros Konstantinides - , Johannes Gutenberg University Mainz (Author)
  • Joachim Meyer - , Munich Municipal Hospital Bogenhausen (Author)
  • Heinrich Worth - , Fürth (Author)
  • Wolfram Windisch - , Cologne City Clinics (Author)
  • Tobias Welte - , Leibniz University Hannover (LUH) (Author)
  • Torsten Bauer - , Helios Hospital Group (Author)

Abstract

Assessing the risk for specific patient groups to suffer from severe courses of COVID-19 is of major importance in the current SARS-CoV-2 pandemic. This review focusses on the risk for specific patient groups with chronic respiratory conditions, such as patients with asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF), sarcoidosis, interstitial lung diseases, lung cancer, sleep apnea, tuberculosis, neuromuscular diseases, a history of pulmonary embolism, and patients with lung transplants. Evidence and recommendations are detailed in exemplary cases. While some patient groups with chronic respiratory conditions have an increased risk for severe courses of COVID-19, an increasing number of studies confirm that asthma is not a risk factor for severe COVID-19. However, other risk factors such as higher age, obesity, male gender, diabetes, cardiovascular diseases, chronic kidney or liver disease, cerebrovascular and neurological disease, and various immunodeficiencies or treatments with immunosuppressants need to be taken into account when assessing the risk for severe COVID-19 in patients with chronic respiratory diseases.

Details

Original languageEnglish
Pages (from-to)307-320
Number of pages14
JournalRespiration
Volume101
Issue number3
Publication statusPublished - 2022
Peer-reviewedYes

External IDs

PubMedCentral PMC8985038
ORCID /0000-0001-6022-6827/work/127318518
Scopus 85124108292
Mendeley db800fd2-3574-3ca1-b1ed-d257034dbc0b

Keywords

Subject groups, research areas, subject areas according to Destatis

Sustainable Development Goals

Keywords

  • COVID-19, Humans, Male, Pandemics, Physicians, Risk Assessment, SARS-CoV-2, Respiratory diseases, Risk assessment